

## References

1. Tsukada N, Ikeda M, Suzuki K, et al. High-dose melphalan and autologous stem cell transplantation for systemic light-chain amyloidosis: a single institution retrospective analysis of 40 cases. *Int J Hematol.* 2016; 103(3):299-305.
2. Muchtar E, Buadi F, Dispenzieri A, Gertz M. Immunoglobulin Light-Chain Amyloidosis: From Basics to New Developments in Diagnosis, Prognosis and Therapy. *Acta Haematol.* 2016; 135(3):172-190.
3. Rajkumar SV. Prognosis and treatment of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases. In: Glasscock RJ, Kyle RA, Schwab SJ, eds. *UpToDate Online* 2017.
4. D'Sa S, Kersten MJ, Castillo JJ, et al. Investigation and management of IgM and Waldenstrom-associated peripheral neuropathies: recommendations from the IWWM-8 consensus panel. *Br J Haematol.* 2017; 176(5):728-742.
5. Afrough A, Saliba RM, Hamdi A, et al. Impact of induction therapy on the outcome of immunoglobulin light chain amyloidosis after autologous hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant.* 2018; 24(11):2197-2203.
6. Gertz MA, Lacy MQ, Dispenzieri A, et al. Stem cell transplantation compared with melphalan plus dexamethasone in the treatment of immunoglobulin light-chain amyloidosis. *Cancer* (0008543X). 2016; 122(14):2197-2205.
7. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Systemic Light Chain Amyloidosis. Version 1 2022.
8. Yeh JC, Shank BR, Milton DR, Qazilbash MH. Adverse prognostic factors for morbidity and mortality during peripheral blood stem cell mobilization in patients with light chain amyloidosis. *Biol Blood Marrow Transplant.* 2018; 24(4):815-819.
9. Nguyen VP, Landau H, Quillen K, et al. Modified high-dose melphalan and autologous stem cell transplantation for immunoglobulin light chain amyloidosis. *Biol Blood Marrow Transplant.* 2018;24(9):1823-1827.
10. Cai Y, Xu S, Li N, Li S, Xu G. Efficacy of chemotherapies and stem cell transplantation for systemic AL amyloidosis: A network meta-analysis. *Front Pharmacol.* 2020;10:1601.
11. Sharpley FA, Petrie A, Mahmood S, Sachchithanatham S, Lachmann HJ, Gillmore JD, et al. A 24-year experience of autologous stem cell

transplantation for light chain amyloidosis patients in the United Kingdom. *Br J Haematol.* 2019;187(5):642-652.